Zacks Investment Research Downgrades Eisai (OTCMKTS:ESALY) to Strong Sell
According to Zacks, “Eisai Co LTD is involved in the Biotechnology and Drug Industry. Their principle activities are the manufacture and sale of pharmaceutical products. Operations are carried out through the following divisions: Pharmaceuticals: veterinary drugs other food additives, livestock feed and pharmaceutical production systems and equipment. The Group has overseas consolidated subsidiaries in the United States, Canada, the United Kingdom, France, Germany, East Southeast Asia and South and Central America. “
Shares of OTCMKTS ESALY opened at $67.16 on Tuesday. The stock has a market cap of $19.92 billion, a PE ratio of 17.35 and a beta of 0.41. The company has a current ratio of 2.48, a quick ratio of 2.11 and a debt-to-equity ratio of 0.13. Eisai has a 12-month low of $63.85 and a 12-month high of $125.00. The company has a 50-day moving average of $69.39 and a 200 day moving average of $75.93.
Eisai Company Profile
Eisai Co, Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures.
Featured Story: How to track put option volume
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eisai Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eisai and related companies with MarketBeat.com's FREE daily email newsletter.